Acute Respiratory Distress Syndrome Clinical Trial
— PARAVENTOfficial title:
Paramedical Protocol for Ventilation in Acute Respiratory Distress Syndrome: Prospective, Multicenter, Randomized, Controlled, Open-label, Phase III, Cluster Trial With Sequential Permutation
Verified date | September 2023 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Acute respiratory distress syndrome (ARDS) is a frequent pathology in intensive care (around 10% of patients admitted to intensive care and almost a quarter of patients on mechanical ventilation) and a serious one, with a hospital mortality rate of 40%. The main measures that have an effect on mortality in ARDS involve adjustments to the ventilator, known as protective ventilation. In the most severe patients, adjuvant measures such as prone positioning and the use of curarisation in the initial phase of the disease can improve survival. All these measures have been included in the latest national and international recommendations. However, a vast observational study carried out in 50 countries revealed low compliance with these recommendations. More than a third of patients did not receive protective ventilation, and the majority did not receive prone positioning when this was indicated. During weaning from artificial ventilation, it has been widely demonstrated that replacing clinician judgement with the implementation of paramedical care protocols improved weaning and significantly reduced the duration of artificial ventilation. Therefore, investigators hypothesize that the implementation of a paramedical care protocol for ventilation in the acute phase of ARDS improves compliance with recommendations and thus reduces mortality and the duration of artificial ventilation. However, implementation of such a protocol requires operational training for all the nurses in the participating departments. Simulation appears to be the training method of choice, as it is a teaching technique that enables technical and non-technical skills to be passed on with good retention of what has been learnt, as well as assessing what has been learnt. To make it possible to train several dozen nurses within a tight timescale, a partially dematerialized simulation model incorporating innovative e-learning tools will be developed.
Status | Not yet recruiting |
Enrollment | 540 |
Est. completion date | August 1, 2025 |
Est. primary completion date | August 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years - Intensive care hospitalization; - Intubation with artificial ventilation; - ARDS evolving for less than 72 hours. ARDS criteria according to the Berlin definition, as follows: - Exposure to a risk factor for ARDS or onset/aggravation of pulmonary symptoms within the previous 7 days ; - Respiratory distress not fully explained by cardiac failure or volume overload, with exclusion of hydrostatic edema in the absence of exposure to a risk factor for ARDS; - Hypoxemia with PaO2/FiO2 ratio < 300 mm Hg under PEEP = 5 cmH2O ; - Bilateral opacities on chest X-ray, lung ultrasound or chest CT, not fully explained by pleural effusions, atelectasis or nodules. - Blood pressure monitoring - Affiliation to the social security system. - Written informed consent (patient, relative) or inclusion in emergency situation. Exclusion Criteria: - Long-term oxygen therapy; - Pneumothorax or drained pleurisy; - Documented pulmonary embolism; - Intracranial hypertension; - ARDS refractory to inclusion, i.e.: i) oxygen partial pressure on inspired oxygen fraction a ratio (PaO2/FiO2) <80 mm Hg or plateau pressure (Pplat) > 32 cmH2O despite optimization of mechanical ventilation (tidal volume (Vt) set at 6 mL/kg weight predicted by height, FiO2 =80% and positive expiratory pressure (PEEP) =10 cmH2O) and despite the use of complementary therapies (including prone and/or inhaled nitric oxide); or ii) pH <7. 25 with PaCO2 =60 mm Hg; - ARDS evolving for more than 72 hours with intubation and mechanical ventilation; - Patient deprived of liberty; - Patient under legal protection (guardianship or curatorship); - Known pregnancy or breast-feeding (a pregnancy test will be performed prior to inclusion in patients of childbearing age). |
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique-Hôpitaux de Paris service de santé publique | Créteil | Creteil |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mortality rate and number of days without mechanical ventilation | The primary endpoint will be a combination of mortality and the number of days without mechanical ventilation at D28. This composite criterion will be prioritised so that survival is given priority in the analysis over the shorter duration of mechanical ventilation. | 28 days | |
Secondary | Mesure of tidal volume ventilation | Up to Day 7 | ||
Secondary | Mesure of plateau pressure | Up to Day 7 | ||
Secondary | Mesure of positive end-expiratory pressure (PEEP) | Up to Day 7 | ||
Secondary | Mesure of FiO2 | Up to Day 7 | ||
Secondary | Oxygenation | arterial blood gases and SpO2 | Up to Day 7 | |
Secondary | Number of days without mechanical ventilation | Up to Day 28 | ||
Secondary | Number of days without catecholamine | Up to Day 28 | ||
Secondary | Number of days without continuous sedation | Up to Day 28 | ||
Secondary | Duration of mechanical ventilation . | from intubation to successful extubation | Up to Day 28 | |
Secondary | Occurrence of mechanically ventilated pneumothorax | Up to Day 28 | ||
Secondary | Duration of Acute respiratory distress syndrome | defined as the day on which the 1st test of spontaneous ventilation was performed | UP to Day 28 | |
Secondary | Duration of weaning from mechanical ventilation | measured as the time between the 1st test of spontaneous ventilation and successful extubation (patient alive and without reintubation within 7 days of extubation). | Up to Day 28 | |
Secondary | Number of participants with rescue therapy | Up to Day 28 | ||
Secondary | Rate of re-intubation | Up to Day 28 | ||
Secondary | Rate of use of non-invasive ventilation and curative high-flow oxygen therapy | Up to Day 28 | ||
Secondary | Tracheostomy rate | Up to Day 28 | ||
Secondary | Length of stay in intensive care and in hospital. | Up to day 28 | ||
Secondary | Number of deaths in ICU and hospital | Up to Day 28 | ||
Secondary | Number of nurses trained in paramedical protocol per center. | Up to 26 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A |